Climb Bio (CLYM) vs Zevra Therapeutics (ZVRA)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
Climb Bio (CLYM) has outperformed Zevra Therapeutics (ZVRA) over the past year, gaining 503.3% versus a gain of 3.4%. Over five years, ZVRA leads with a +12.6% price change compared with -32.7% for CLYM. Zevra Therapeutics is the larger company by market cap ($676.4 million vs $631.8 million), about 1.1 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | CLYM | ZVRA |
|---|---|---|
| Share price | $11.00 | $11.39 |
| Market cap | $631.80M | $676.38M |
| 1-day change | +1.29% | +3.55% |
| YTD return | +171.50% | +22.77% |
| 1-year return | +503.33% | +3.38% |
| 5-year return | -32.71% | +12.59% |
| P/E ratio (TTM) | — | 12.38 |
| Forward P/E | — | 10.58 |
| EPS (TTM) | $-0.82 | $0.92 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $18.33 | $15.04 |
| 52-week low | $1.64 | $8.01 |
| Distance from 52-week high | -39.99% | -24.24% |
| Analyst consensus | strong_buy | strong_buy |
| Avg. price target upside | +150.64% | +119.49% |
| Average volume | 1.37M | 1.11M |
| Shares outstanding | 57.44M | 59.38M |
| Employees | 28 | 61 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- CLYM has outperformed ZVRA by 499.9 percentage points over the past year.
About Climb Bio
CLYM stock →Climb Bio, Inc., a clinical-stage biotechnology company, focuses on developing therapies to address unmet needs for patients living with immune-mediated diseases. The company's lead product candidate is the budoprutug, an anti-CD19 monoclonal antibody for the treatment of B-cell mediated diseases.
Health Care · Biotechnology: Pharmaceutical Preparations · 28 employees
About Zevra Therapeutics
ZVRA stock →Zevra Therapeutics, Inc., a commercial-stage company, focuses on addressing unmet needs for the treatment of rare diseases in the United States. The company develops its products through Ligand Activated Technology platform.
Health Care · Biotechnology: Pharmaceutical Preparations · 61 employees
CLYM vs ZVRA FAQ
Which is bigger, Climb Bio or Zevra Therapeutics?
Zevra Therapeutics (ZVRA) is larger, with a market capitalization of $676.38M compared with $631.80M for Climb Bio (CLYM).
Which stock has performed better over the past year, CLYM or ZVRA?
CLYM returned +503.33% over the past 12 months, compared with +3.38% for ZVRA (price return, excluding dividends). Past performance does not predict future results.
Are Climb Bio and Zevra Therapeutics in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.